Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 25;50(3):277-286.
doi: 10.13702/j.1000-0607.20240402.

[Electroacupuncture improves colonic mucosal barrier damage by regulating NLRP3/Caspase-1/GSDMD signaling pathway and inhibiting pyroptosis in ulcerative colitis mice]

[Article in Chinese]
Affiliations
Free article

[Electroacupuncture improves colonic mucosal barrier damage by regulating NLRP3/Caspase-1/GSDMD signaling pathway and inhibiting pyroptosis in ulcerative colitis mice]

[Article in Chinese]
Xi-Han Wang et al. Zhen Ci Yan Jiu. .
Free article

Abstract

Objectives: To observe the effect of electroacupuncture (EA) at "Tianshu" (ST25) and "Zusanli" (ST36) on NOD-like receptor protein 3(NLRP3)/cysteine aspartate specific protease 1 (Caspase-1)/gasdermin D (GSDMD) pyroptosis signaling pathway in ulcerative colitis (UC) mice, so as to explore its mechanism in improving UC by protecting intestinal barrier.

Methods: Fifty male C57BL/6 mice were randomly divided into normal, model, EA, sham acupuncture and medication groups, with 10 mice in each group. The UC mouse model was established by 3% DSS solution free drinking for 7 consecutive days. The mice in the EA group received EA (2 Hz/10 Hz, 0.2 mA) at bilateral ST25 and ST36 for 20 min, while the mice in the sham acupuncture group received only sham acupuncture (light and shallow acupunture at ST25 and ST36). Mice in the medication group were orally administered mesalazine (33.4 g/kg) solution. All the interventions were performed once daily for a total of 7 days. The changes of body weight, stool shape and hematochezia of mice, the disease activity index (DAI) score, and the length of colon were recorded. The intestinal mucosal permeability was observed by in vivo small animal imaging system. HE staining was used to observe the pathological changes of colon tissue. TUNEL staining was used to observe the apoptosis of colon cells. The contents of interleukin (IL)-18 and IL-1β in serum were detected by ELISA. The average fluorescence intensity of tumor necrosis factor-α (TNF-α) and IL-6 in colon tissue was detected by immunofluorescence. The positive expression of IL-18 and IL-1β in colon tissue was detected by immunohistochemistry. The relative expression levels of zonula occludens-1 (ZO-1), Occludin, NLRP3, Caspase-1 and GSDMD in colon tissue were detected by Western blot. The mRNA expressions of NLRP3, Caspase-1 and GSDMD in colon tissue were detected by qPCR.

Results: After modeling, the DAI, inflammatory infiltration, number of apoptotic cells, fluorescence intensity of TNF-α, IL-6 and FITC, positive expression rate of IL-18 and IL-1β, mRNA and protein expression levels of NLRP3, Caspase-1 and GSDMD, serum IL-18 and IL-1β contents were significantly increased (P<0.01) in the model group relevant to the normal group. At the same time, the colon length, ZO-1 and Occludin protein expression were significantly reduced (P<0.01). The increased DAI, inflammatory infiltration, number of apoptotic cells, fluorescence intensity of TNF-α, IL-6 and FITC, positive rate of IL-18 and IL-1β, mRNA and protein expression levels of NLRP3, Caspase-1 and GSDMD, serum IL-18 and IL-1β contents, and the decreased colon length, ZO-1 and Occludin protein expression were all reversed after the EA and medication interventions compared with the model group and in the EA group than in the sham acupuncture group (P<0.01, P<0.05).

Conclusions: EA can protect the intestinal mucosal permeability in UC mice, which may be related to its functions in regulating the NLRP3/Caspase-1/GSDMD axis and inhibiting pyroptosis, thereby alleviating the inflammatory injury of intestinal mucosa.

目的: 观察电针“天枢”“足三里”对溃疡性结肠炎(UC)小鼠的NOD样受体蛋白3(NLRP3)/半胱氨酸天冬氨酸特异性蛋白酶1(Caspase-1)/消皮素D(GSDMD)细胞焦亡信号通路的影响,探讨电针通过保护肠道屏障进而改善UC的相关机制。方法: C57BL/6小鼠随机分为正常组、模型组、电针组、假针刺组和西药组,10只/组。采用每日3%葡聚糖硫酸钠自由饮用的方法建立UC小鼠模型,同时给予对应治疗,电针组电针双侧“天枢”“足三里”,假针刺组仅浅刺入穴位皮下不通电,西药组予美沙拉嗪溶液(33.4 g/kg)灌胃。记录小鼠体质量变化、粪便性状和便血情况并计算疾病活动指数(DAI)评分,测量结肠长度;利用小动物活体成像系统观察小鼠肠黏膜通透性FITC荧光信号强度;HE染色法观察小鼠结肠组织病理变化;TUNEL染色观察小鼠结肠组织细胞凋亡情况;ELISA法检测小鼠血清白细胞介素(IL)-18和IL-1β含量;免疫荧光法检测小鼠结肠组织中肿瘤坏死因子α(TNF-α)、IL-6平均荧光强度;免疫组织化学法检测小鼠结肠组织中IL-18、IL-1β 阳性表达;Western blot法检测小鼠结肠组织中闭锁小带蛋白-1(ZO-1)、闭锁蛋白(Occludin)、NLRP3、Caspase-1和GSDMD的蛋白相对表达量;qPCR法检测各组小鼠结肠组织NLRP3、Caspase-1和GSDMD mRNA表达。结果: 与正常组相比,模型组小鼠DAI评分升高(P<0.01),结肠长度缩短(P<0.01),结肠组织出现炎性浸润,绒毛和隐窝结构显著破坏,凋亡细胞数量增多(P<0.01),TNF-α、IL-6与肠道FITC荧光强度增强(P<0.01),IL-18、IL-1β阳性表达升高(P<0.01),结肠组织NLRP3、Caspase-1、GSDMD蛋白相对表达量升高(P<0.01),NLRP3、Caspase-1、GSDMD mRNA表达水平升高(P<0.01),ZO-1、Occludin蛋白相对表达量降低(P<0.01),血清IL-18、IL-1β含量升高(P<0.01)。电针组和西药组与模型组相比及电针组与假针刺组比较,小鼠毛色光泽度高,活动度高,DAI评分显著降低(P<0.01),结肠长度增加(P<0.01),小鼠结肠黏膜形态相对完好,腺体排列较为有序,绒毛排列相对整齐,隐窝结构恢复较好,炎性渗出减少,凋亡细胞数量减少(P<0.01),结肠组织TNF-α、IL-6与肠道FITC荧光强度减弱(P<0.01),IL-18、IL-1β阳性表达降低(P<0.01),NLRP3、Caspase-1、GSDMD蛋白相对表达量降低(P<0.05,P<0.01),NLRP3、Caspase-1、GSDMD mRNA表达水平降低(P<0.01),ZO-1、Occludin蛋白相对表达量升高(P<0.05,P<0.01),血清IL-18、IL-1β含量降低(P<0.01,P<0.05)。结论: 电针“天枢”“足三里”可以恢复UC小鼠结肠黏膜通透性,其机制可能与调控NLRP3/Caspase-1/GSDMD轴抑制细胞焦亡,改善肠黏膜炎性损伤有关。.

Keywords: Electroacupuncture; Intestinal barrier; Pyroptosis; Ulcerative colitis.

PubMed Disclaimer

Similar articles

References

    1. NG S C, SHI H Y, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778.
    1. UNGARO R, MEHANDRU S, ALLEN P, et al. Ulcerative colitis[J]. Lancet, 2017, 389: 1756-1770.
    1. NG S C, SHI H Y, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778.
    1. GAJENDRAN M, LOGANATHAN P, JIMENEZ G, et al. A comprehensive review and update on ulcerative colitis[J]. Dis Mon, 2019, 65(12): 100851.
    1. PUGLIESE N, RODA G, PEYRIN-BIROULET L, et al. Emerging therapies for the treatment of ulcerative colitis[J]. Expert Opin Emerg Drugs, 2020: 1-9.

Publication types

MeSH terms

Substances

LinkOut - more resources